Edgar Filing: SANGAMO BIOSCIENCES INC - Form 4

SANGAMO Form 4 May 29, 20	D BIOSCIENCES	INC									
FORM	ЛЛ	STATES	SECUI	RITIES .	AND EX	СНА	NGE CO	OMMISSION	OMB AF	PPROVAL	
Check t	Washington, D.C. 20549								Number:	3235-0287	
Check this box if no longer subject to Section 16. Form 4 or Form 5 Eiled pursuant to				SECU	RITIES		ERSHIP OF Act of 1934,	Expires: January Estimated average burden hours per response			
obligatio may cor <i>See</i> Inst 1(b).	ons Section 170	(a) of the H	Public U	Itility Ho		npany	y Act of	1935 or Section	l		
(Print or Type	Responses)										
ANDO DALE G Sym SA			Symbol	ANGAMO BIOSCIENCES INC				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 3. D (Mo				Date of Earliest Transaction				Director 10% Owner Officer (give title Other (specify below) VP, Therapeutic Dev. & CMO			
RICHMON	(Street) JD, CA 94804			endment, E onth/Day/Yea	Date Origina ar)	1		6. Individual or Joi Applicable Line) _X_ Form filed by O Form filed by Mo	ne Reporting Pe	rson	
(City)	(State)	(Zip)				a		Person			
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	-	ed Date, if	3. Transacti Code (Instr. 8)	4. Securit oror Dispos (Instr. 3, 4	ies Ac ed of (4 and 5 (A) or	quired (A) D) 5)	ired, Disposed of, 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	ly Owned 7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	05/27/2014			Code V M	Amount 13,000	(D) A	Price \$ 3.45	111,377 <u>(2)</u> (3)	D		
Common Stock	05/27/2014			S <u>(1)</u>	13,000	D	\$ 13.569 (4)	98,377 <u>(2)</u> <u>(3)</u>	D		
Common Stock	05/27/2014			М	2,000	А	\$ 5.19	100,377 <u>(2)</u> (3)	D		
Common Stock	05/27/2014			S <u>(1)</u>	2,000	D	\$ 13.567	98,377 <u>(2)</u> <u>(3)</u>	D		

Edgar Filing: SANGAMO BIOSCIENCES INC - Form 4

(5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration I (Month/Day	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Employee Stock Option (Right to Buy)	\$ 3.45	05/27/2014		М	13,000	<u>(6)</u>	12/09/2018	Common Stock	13,000	
Employee Stock Option (Right to Buy)	\$ 5.19	05/27/2014		М	2,000	<u>(6)</u>	12/19/2014	Common Stock	2,000	

Reporting Owners

Reporting Owner Name / Address		Relationships					
Reporting Owner Par	Director	10% Owner	Officer	Other			
ANDO DALE G C/O SANGAMO BIOSCIENCES INC. POINT RICHMOND TECH CNTR, 501 CANAL BLVD RICHMOND, CA 94804				VP, Therapeutic Dev. & CMO			
Signatures							
/s/ Florence Tam, attorney-in-fact	05/29/2014						
<u>**</u> Signature of Reporting Person	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 25, 2013.
- (2) Includes 33,333 shares, 23,333 shares, and 23,000 shares subject to restricted stock units granted on December 8, 2011, December 6, 2012, and December 12, 2013, respectively, that will be issued as such units vest in accordance with their terms.
- (3) Includes 1,362 shares acquired by the Reporting Person on April 30, 2014 under the Issuer's Employee Stock Purchase Plan.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$13.39 to \$12.62 inclusive. The Departing Department and tables to provide to Songerne Dis Sciences. Inc., any country holder of Songerne.

to \$13.63, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$13.44 to \$13.63, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo

- (5) BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- (6) All shares underlying this option are vested and immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.